Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Androgen Receptor in Prostate Cancer: Effect of Structure, Ligands and Spliced Variants on Therapy
Elisabeth A. Messner, Thomas M. Steele, Maria Malvina Tsamouri, et al.
Biomedicines (2020) Vol. 8, Iss. 10, pp. 422-422
Open Access | Times Cited: 64

Showing 1-25 of 64 citing articles:

Androgenetic alopecia: An update
Sincengile Nokubonga Ntshingila, Ogheneochuko Oputu, Afolake Arowolo, et al.
JAAD International (2023) Vol. 13, pp. 150-158
Open Access | Times Cited: 46
Androgen Receptor-Dependent Mechanisms Mediating Drug Resistance in Prostate Cancer
Marzieh Ehsani, Faith Oluwakemi David, Aria Baniahmad
Cancers (2021) Vol. 13, Iss. 7, pp. 1534-1534
Open Access | Times Cited: 61
AR and PI3K/AKT in Prostate Cancer: A Tale of Two Interconnected Pathways
Elisabetta Tortorella, Sabrina Giantulli, Alessandro Sciarra, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2046-2046
Open Access | Times Cited: 38
Addressing the Reciprocal Crosstalk between the AR and the PI3K/AKT/mTOR Signaling Pathways for Prostate Cancer Treatment
Fabio Raith, Daniel H. O’Donovan, Clara Lemos, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2289-2289
Open Access | Times Cited: 23
Insight into Recent Advances in Degrading Androgen Receptor for Castration-Resistant Prostate Cancer
Qiao‐Hong Chen, Erick Munoz, Dennis Ashong
Cancers (2024) Vol. 16, Iss. 3, pp. 663-663
Open Access | Times Cited: 15
Looking beyond the ER, PR, and HER2: what’s new in the ARsenal for combating breast cancer?
Tryambak Srivastava, Ruby Dhar, Subhradip Karmakar
Reproductive Biology and Endocrinology (2025) Vol. 23, Iss. 1
Open Access | Times Cited: 1
Targeting DNA Damage Response in Prostate and Breast Cancer
Antje M. Wengner, Arne Scholz, Bernard Haendler
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 21, pp. 8273-8273
Open Access | Times Cited: 69
An Overview of Next-Generation Androgen Receptor-Targeted Therapeutics in Development for the Treatment of Prostate Cancer
Michael L. Mohler, Arunima Sikdar, Suriyan Ponnusamy, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 4, pp. 2124-2124
Open Access | Times Cited: 54
A Comprehensive Overview of Small-Molecule Androgen Receptor Degraders: Recent Progress and Future Perspectives
Si Ha, Guoshun Luo, Hua Xiang
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 24, pp. 16128-16154
Closed Access | Times Cited: 24
Liquid-Based Diagnostic Panels for Prostate Cancer: The Synergistic Role of Soluble PD-L1, PD-1, and mRNA Biomarkers
Margarita Žvirblė, Ieva Vaicekauskaitė, Žilvinas Survila, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 2, pp. 704-704
Open Access
The Role of Androgens and Androgen Receptor in Human Bladder Cancer
Elizabeth Martínez-Rojo, Laura C. Berumen, Guadalupe García‐Alcocer, et al.
Biomolecules (2021) Vol. 11, Iss. 4, pp. 594-594
Open Access | Times Cited: 29
Non-genomic signaling of steroid receptors in cancer
C. Thiébaut, Virginie Vlaeminck‐Guillem, Olivier Trédan, et al.
Molecular and Cellular Endocrinology (2021) Vol. 538, pp. 111453-111453
Open Access | Times Cited: 29
A phase 1 study to assess the safety, pharmacokinetics, and anti-tumor activity of the androgen receptor n-terminal domain inhibitor epi-506 in patients with metastatic castration-resistant prostate cancer
Corinne Maurice‐Dror, Ronan Le Moigne, Ulka N. Vaishampayan, et al.
Investigational New Drugs (2021) Vol. 40, Iss. 2, pp. 322-329
Closed Access | Times Cited: 29
An update on nanocarriers for follicular-targeted drug delivery for androgenetic alopecia topical treatment
Jayanaraian F. M. Andrade, Andrew Verbinnen, A. W. Bakst, et al.
Expert Opinion on Drug Delivery (2025)
Closed Access
AR activates YAP/TAZ differentially in prostate cancer
Omar Salem, Siyang Jia, Bin‐Zhi Qian, et al.
Life Science Alliance (2023) Vol. 6, Iss. 9, pp. e202201620-e202201620
Open Access | Times Cited: 10
Beyond Prostate Cancer: An Androgen Receptor Splice Variant Expression in Multiple Malignancies, Non-Cancer Pathologies, and Development
Kimberley Katleba, P. Ghosh, Maria Mudryj
Biomedicines (2023) Vol. 11, Iss. 8, pp. 2215-2215
Open Access | Times Cited: 9
Unveiling the latest insights into Androgen Receptors in Prostate Cancer
Suleiman Zakari
International journal of medical biochemistry/International journal of medical biochemistry : (2024), pp. 101-113
Open Access | Times Cited: 3
Undesirable Status of Prostate Cancer Cells after Intensive Inhibition of AR Signaling: Post-AR Era of CRPC Treatment
Tomoyuki Makino, Kouji Izumi, Atsushi Mizokami
Biomedicines (2021) Vol. 9, Iss. 4, pp. 414-414
Open Access | Times Cited: 21
Advances in the Current Understanding of the Mechanisms Governing the Acquisition of Castration-Resistant Prostate Cancer
Yifeng Mao, Gaowei Yang, Yingbang Li, et al.
Cancers (2022) Vol. 14, Iss. 15, pp. 3744-3744
Open Access | Times Cited: 15
Exploring the therapeutic potential of Neem (Azadirachta Indica) for the treatment of prostate cancer: a literature review
Neelu Batra, Vigneshwari Easwar Kumar, R Nambiar, et al.
Annals of Translational Medicine (2022) Vol. 10, Iss. 13, pp. 754-754
Open Access | Times Cited: 14
Targeting the N-terminal domain of the androgen receptor: The effective approach in therapy of CRPC
Yang Ji, Rongyu Zhang, Xiaoli Han, et al.
European Journal of Medicinal Chemistry (2022) Vol. 247, pp. 115077-115077
Closed Access | Times Cited: 14
Prostate cancer and bone: clinical presentation and molecular mechanisms
Kristina V Wells, Margaret Li Krackeler, Maitreyee K. Jathal, et al.
Endocrine Related Cancer (2023) Vol. 30, Iss. 9
Open Access | Times Cited: 8
Advances in the understanding of androgen receptor structure and function and in the development of next-generation AR-targeted therapeutics
Wendy Effah, Marjana Khalil, Dong‐Jin Hwang, et al.
Steroids (2024) Vol. 210, pp. 109486-109486
Closed Access | Times Cited: 2
Primary Osteoporosis Induced by Androgen and Estrogen Deficiency: The Molecular and Cellular Perspective on Pathophysiological Mechanisms and Treatments
S.Y.C. Hsu, Li-Ru Chen, Kuo-Hu Chen
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 22, pp. 12139-12139
Open Access | Times Cited: 2
The catalytic subunit of DNA-PK regulates transcription and splicing of AR in advanced prostate cancer
Beth Adamson, Nicholas Brittain, Laura Walker, et al.
Journal of Clinical Investigation (2023) Vol. 133, Iss. 22
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top